Fonte: Pharmacological Research. Unidades: FMRP, FCFRP
Assuntos: AORTA TORÁCICA, AORTA TORÁCICA, PRESSÃO SANGUÍNEA, CÁLCIO, HIPERTENSÃO, NOREPINEFRINA
ABNT
POTJE, Simone Regina et al. Glypican 1 and syndecan 1 differently regulate noradrenergic hypertension development: focus on IP3R and calcium. Pharmacological Research, v. 172, p. 1-11, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.phrs.2021.105813. Acesso em: 06 nov. 2024.APA
Potje, S. R., Isbatan, A., Tostes, R. de C. A., Bendhack, L. M., Dull, R. O., Carvalho-de-Souza, J. L., & Chignalia, A. Z. (2021). Glypican 1 and syndecan 1 differently regulate noradrenergic hypertension development: focus on IP3R and calcium. Pharmacological Research, 172, 1-11. doi:10.1016/j.phrs.2021.105813NLM
Potje SR, Isbatan A, Tostes R de CA, Bendhack LM, Dull RO, Carvalho-de-Souza JL, Chignalia AZ. Glypican 1 and syndecan 1 differently regulate noradrenergic hypertension development: focus on IP3R and calcium [Internet]. Pharmacological Research. 2021 ; 172 1-11.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.phrs.2021.105813Vancouver
Potje SR, Isbatan A, Tostes R de CA, Bendhack LM, Dull RO, Carvalho-de-Souza JL, Chignalia AZ. Glypican 1 and syndecan 1 differently regulate noradrenergic hypertension development: focus on IP3R and calcium [Internet]. Pharmacological Research. 2021 ; 172 1-11.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.phrs.2021.105813